Following a successful HIMSS24, MedApp is ready for the next step towards the US market – establishing a subsidiary in the United States to respond effectively to the needs of American partners and customers.
A few weeks have passed since the HIMSS24 medical technology trade show in Orlando, Florida, where we successfully presented our unique mixed reality 3D holographic imaging technology, CarnaLife Holo. We met with a very positive reception from both physicians and the business community. We are now ready to take the next step towards entering the US market by establishing a subsidiary in the United States.
Having a company in the US is a natural step so that we can respond effectively to the needs of American partners and customers. This move is the next stage in the commercialisation of CarnaLife Holo in the US, as we already hold FDA clearance admitting our product to this market.
The company's portfolio also includes new products such as CarnaLife Holo MedNav – the world's first tool for actively supporting physicians in performing all types of needle biopsies, based on mixed reality (MR) and spatial holographic visualisation. The system supports the precision, comfort and safety of medical procedures.
Discover CarnaLife Holo MedNavThe latest on MedApp, CarnaLife Holo and our deployments.
MedApp's augmented reality and AI-based solutions can support physicians in military hospitals and in operational conditions. The company holds an NCAGE code, and its subsidiary has applied for a licence to trade in military-purpose technology.
Read moreThe Management Board informs about actions taken by the Social Insurance Institution (ZUS) regarding the Issuer's liabilities and the application submitted to pay the amounts due in instalments. Maintaining operational continuity remains the priority.
Read moreOn 27–30 October 2025 MedApp presents CarnaLife Holo at the Global Health Exhibition in Riyadh – one of the largest healthcare events in the world. Find us in Hall H1A, stand PODS64.
Read more
